ArticleFrontiers in public health2022
How to control the spatiotemporal spread of Omicron in the region with low vaccination rates.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, finding ways to effectively control the spread of Omicron in regions with low vaccination rates is an urgent issue. In this study, we use a district-level model for predicting the COVID-19 symptom onset risk to explore and control the whole process of spread of Omicron in South Africa at a finer spatial scale. We found that in the early stage of the accelerated spread, Omicron spreads rapidly from the districts at the center of human mobility to other important districts of the human mobility network and its peripheral districts. In the subsequent diffusion-contraction stage, Omicron rapidly spreads to districts with low human mobility and then mainly contracts to districts with the highest human mobility. We found that increasing daily vaccination rates 10 times mainly reduced the symptom onset risk in remote areas with low human mobility. Implementing Alert Level 5 in the three districts at the epicenter, and Alert Level 1 in the remaining 49 districts, the spatial spread related to human mobility was effectively restricted, and the daily onset risk in districts with high human mobility also decreased by 20-80%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.